ev3 Inc. 

(Public, NASDAQ:EVVV)   Watch this stock   
Find more results for EVVV
Dec 1, 2009
Piper Jaffray Healthcare Conference - 8:30AM EST - Add to calendar
Nov 19, 2009
Citi Healthcare Conference
Oct 27, 2009
Q3 2009 Earnings Release
Sep 14, 2009
Morgan Stanley Global Healthcare Unplugged Conference - Webcast
Sep 10, 2009
Thomas Weisel Partners Healthcare Conference
Aug 25, 2009
Barrington Research Healthcare Conference
More events from AOL Finance »    

Key stats and ratios

Q4 (Oct '09) 2008
Net profit margin 5.97% -79.51%
Operating margin 6.72% -78.67%
EBITD margin - -68.59%
Return on average assets 3.13% -37.13%
Return on average equity 3.69% -41.98%
Employees 1,250 -

Address

9600 54th Avenue North Suite 1000
Plymouth, MN 55442
United States - Map
+1-763-3987000 (Phone)
+1-763-3987200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

ev3 Inc. discussed on blogs

Ranking 1500+ Small Cap Stocks by Year-to-Date Performance ... - Investor's Resources - NASD100.com - Daily Stock Rankings - Nov 20, 2009

ev3 Inc. discussions

  View all discussions »

Description

ev3 Inc. (ev3) is a global endovascular company focused on identifying and treating peripheral vascular disease, including in particular lower extremity arterial disease, and neurovascular disease. The Company is developing technologies and solutions for the treatment of peripheral vascular and neurovascular diseases. The Company’s product portfolio includes a spectrum of over 100 products consisting of over 1,500 stock keeping units (SKUs), including stents, atherectomy plaque excision products, embolic protection and thrombectomy devices, and percutaneous transluminal angioplasty, or PTA balloons and other procedural support products for the peripheral vascular market and embolic coils, liquid embolics, micro catheters, flow directional catheters, occlusion balloon systems and neuro stents for the neurovascular market.

Officers and directors

Daniel J. Levangie
Chairman of the Board
Age: 58
Bio & Compensation - Reuters
Robert J. Palmisano
President, Chief Executive Officer, Director
Age: 64
Bio & Compensation - Reuters
Shawn T. McCormick
Chief Financial Officer, Senior Vice President
Age: 44
Bio & Compensation - Reuters
Stacy Enxing Seng
Executive Vice President; President- U.S. Peripheral Vascular
Age: 44
Bio & Compensation - Reuters
Pascal E.R. Girin
Executive Vice President; President - Worldwide Neurovascular and International
Age: 49
Bio & Compensation - Reuters
Kevin M. Klemz
Senior Vice President, Secretary, Chief Legal Officer
Age: 47
Bio & Compensation - Reuters
Gregory Morrison
Senior Vice President - Human Resources
Age: 45
Bio & Compensation - Reuters
David H. Mowry
Senior Vice President-Strategic and Corporate Operations
Age: 46
Bio & Compensation - Reuters
Julie D. Tracy
Senior Vice President, Chief Communications Officer
Age: 47
Bio & Compensation - Reuters
Thomas E. Timbie
Director
Age: 51
Bio & Compensation - Reuters